Age-related Macular Degeneration (AMD) is the most common cause of blindness among elderly in the industrialised world, affecting more than 35 million people globally. AMD presents as a progressive loss of vision in the centre of the visual field resulting in a blurred area or blank spot in the centre of vision. With ageing, AMD progresses to an advanced stage becoming increasingly difficult for patients to recognise faces, drive read and/or perform other activities of daily life. The overall UK prevalence of AMD is 2.4% with a sharp age related increase in occurrence of 4.8% of people over 65 and as many as 12.2% over 80 years of age. This is a natural history study in genetically defined patients with geographic atrophy secondary to age-related macular degeneration (AMD). It is expected that approximately 350 patients with AMD will be recruited globally, across North America and Europe. This study consists of 6 visits over approximately 96 weeks, where they will undergo assessments and procedures to assess the natural progression of the disease.
- Home
- COVID-19
-
- FOCUS: A study to test a new treatment for dry AMD
- Gilead
- Investigation of protein defects in retinal degenerations
- MACTEL
- MACTEL PHASE 3- NTMT-03
- MERIT
- Natural History Of Choroideremia (Night Study)
- PressOp™
- Regenerate
- SANDMAN
- SCOPE
- SeaSTAR
- Somnus Sleep Wake Study
- STAR trial (phase 3 gene therapy)
- UK Inherited Retinal Disease Consortium (UKIRDC)
- XIRIUS – Phase I/II Study of Retinal Gene Therapy for X-linked Retinitis Pigmentosa
- Xolaris (X-linked RP observational study)
- Meet the team
- Contact us